Sponsors: Booz Allen Hamilton, Goldman Sachs
Session A) FDA Regulatory Compliance Update
- Election year 2004 - Major potential changes in regulatory
compliance
- FDA’s strides in speeding up drug approvals
- Regulations in manufacturing, clinical and marketing and
compliance
- Medicare and Medicaid - Public purchaser demands and negotiating
State and Federal contracts
Session B) Advances in Research and Development Productivity
- Strategies to increase output productivity in research labs
- Designing treatments targeting specific gene malfunctions or
abnormalities that cause disease
- Role of new technologies and genomics
- Specific metrics to improve productivity
Frank Douglas, Executive Vice President for Drug Innovation and
Approval, and Chief Scientific Officer, Aventis Pharmaceuticals
Session C) Advances in Research and Development Productivity
- Analysis of changing market conditions for utilization and
access to drugs
- Building the case for the value of pharmaceuticals and
determining whether insurers will pay
- How consumerism will impact Medicare and Medicaid populations
Session D) Evolving Customer Relationships - Partnership Strategies
with Health Plans and PBMs
- Strategic and direct negotiations with health plans
- Meeting new demands of consumers and employers
- Consumer demands for portability of benefits
- Integrate medical and pharmaceutical benefit
Barbara Hill, President, Express Scripts
Session E) Building Disease Management Programs to Extend Value and
Cost-Effectiveness
- Expanding role for pharmaceutical companies to provide
cost-effective programs for employers
- Leveraging technology to produce positive disease management
outcomes
- Offering value-added disease management products for PBMs and
health plans
Session F) Genomics and the Commercialization of
Bio-Pharmaceuticals
- Moving the healthcare industry to a “predict and prevent” model
- Future of personalized medicine and decision support
|
